19.77 USD
+0.38 (+1.96%)
ADMA gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. ADMA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ADMA is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings would make ADMA suitable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year ADMA was profitable.
ADMA had a positive operating cash flow in the past year.
In the past 5 years ADMA reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: ADMA reported negative operating cash flow in multiple years.
1.2 Ratios
ADMA has a Return On Assets of 36.83%. This is amongst the best in the industry. ADMA outperforms 98.68% of its industry peers.
ADMA has a better Return On Equity (48.57%) than 98.68% of its industry peers.
Looking at the Return On Invested Capital, with a value of 25.76%, ADMA belongs to the top of the industry, outperforming 98.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROIC | 25.76% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 42.87%, ADMA belongs to the top of the industry, outperforming 97.93% of the companies in the same industry.
ADMA's Operating Margin of 34.19% is amongst the best of the industry. ADMA outperforms 97.36% of its industry peers.
With a decent Gross Margin value of 54.71%, ADMA is doing good in the industry, outperforming 76.65% of the companies in the same industry.
In the last couple of years the Gross Margin of ADMA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so ADMA is creating value.
ADMA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ADMA has been increased compared to 5 years ago.
The debt/assets ratio for ADMA has been reduced compared to a year ago.
2.2 Solvency
ADMA has an Altman-Z score of 22.18. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
ADMA has a better Altman-Z score (22.18) than 90.02% of its industry peers.
The Debt to FCF ratio of ADMA is 1.78, which is an excellent value as it means it would take ADMA, only 1.78 years of fcf income to pay off all of its debts.
ADMA has a Debt to FCF ratio of 1.78. This is amongst the best in the industry. ADMA outperforms 93.60% of its industry peers.
A Debt/Equity ratio of 0.16 indicates that ADMA is not too dependend on debt financing.
ADMA's Debt to Equity ratio of 0.16 is on the low side compared to the rest of the industry. ADMA is outperformed by 66.10% of its industry peers.
Even though the debt/equity ratio score it not favorable for ADMA, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Altman-Z | 22.18 |
ROIC/WACC2.94
WACC8.77%
2.3 Liquidity
A Current Ratio of 7.13 indicates that ADMA has no problem at all paying its short term obligations.
With a decent Current ratio value of 7.13, ADMA is doing good in the industry, outperforming 70.43% of the companies in the same industry.
A Quick Ratio of 3.65 indicates that ADMA has no problem at all paying its short term obligations.
ADMA's Quick ratio of 3.65 is in line compared to the rest of the industry. ADMA outperforms 45.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 92.86% over the past year.
The Revenue has grown by 27.62% in the past year. This is a very strong growth!
ADMA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 70.84% yearly.
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
3.2 Future
The Earnings Per Share is expected to grow by 33.90% on average over the next years. This is a very strong growth
Based on estimates for the next years, ADMA will show a very strong growth in Revenue. The Revenue will grow by 21.48% on average per year.
EPS Next Y19.68%
EPS Next 2Y36.5%
EPS Next 3Y36.8%
EPS Next 5Y33.9%
Revenue Next Year20.91%
Revenue Next 2Y22.61%
Revenue Next 3Y24.25%
Revenue Next 5Y21.48%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 36.61, which means the current valuation is very expensive for ADMA.
Compared to the rest of the industry, the Price/Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 91.90% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of ADMA to the average of the S&P500 Index (26.34), we can say ADMA is valued slightly more expensively.
With a Price/Forward Earnings ratio of 21.22, ADMA is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 94.16% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.56, ADMA is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.61 | ||
| Fwd PE | 21.22 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ADMA is valued cheaper than 93.22% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ADMA is valued cheaply inside the industry as 91.15% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 115.87 | ||
| EV/EBITDA | 26.43 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ADMA does not grow enough to justify the current Price/Earnings ratio.
ADMA has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ADMA's earnings are expected to grow with 36.80% in the coming years.
PEG (NY)1.86
PEG (5Y)N/A
EPS Next 2Y36.5%
EPS Next 3Y36.8%
5. Dividend
5.1 Amount
No dividends for ADMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ADMA (12/9/2025, 12:01:26 PM)
19.77
+0.38 (+1.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners93.44%
Inst Owner Change5.68%
Ins Owners2.35%
Ins Owner Change-0.83%
Market Cap4.71B
Revenue(TTM)488.56M
Net Income(TTM)209.45M
Analysts84
Price Target27.8 (40.62%)
Short Float %8.15%
Short Ratio5.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.96%
Min EPS beat(2)-1.96%
Max EPS beat(2)-1.96%
EPS beat(4)0
Avg EPS beat(4)-10.9%
Min EPS beat(4)-31.17%
Max EPS beat(4)-1.96%
EPS beat(8)3
Avg EPS beat(8)-42.78%
EPS beat(12)6
Avg EPS beat(12)-7.71%
EPS beat(16)8
Avg EPS beat(16)-5.59%
Revenue beat(2)1
Avg Revenue beat(2)-0.85%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)0.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.71%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)2.16%
Revenue beat(8)6
Avg Revenue beat(8)4.26%
Revenue beat(12)10
Avg Revenue beat(12)4.8%
Revenue beat(16)14
Avg Revenue beat(16)6.2%
PT rev (1m)0%
PT rev (3m)-6.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.66%
EPS NY rev (1m)-1.12%
EPS NY rev (3m)2.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.84%
Revenue NY rev (1m)0.92%
Revenue NY rev (3m)0.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.61 | ||
| Fwd PE | 21.22 | ||
| P/S | 9.63 | ||
| P/FCF | 115.87 | ||
| P/OCF | 72.42 | ||
| P/B | 10.91 | ||
| P/tB | 11.02 | ||
| EV/EBITDA | 26.43 |
EPS(TTM)0.54
EY2.73%
EPS(NY)0.93
Fwd EY4.71%
FCF(TTM)0.17
FCFY0.86%
OCF(TTM)0.27
OCFY1.38%
SpS2.05
BVpS1.81
TBVpS1.79
PEG (NY)1.86
PEG (5Y)N/A
Graham Number4.69
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 36.83% | ||
| ROE | 48.57% | ||
| ROCE | 32.61% | ||
| ROIC | 25.76% | ||
| ROICexc | 29.27% | ||
| ROICexgc | 29.53% | ||
| OM | 34.19% | ||
| PM (TTM) | 42.87% | ||
| GM | 54.71% | ||
| FCFM | 8.31% |
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.86
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.16 | ||
| Debt/FCF | 1.78 | ||
| Debt/EBITDA | 0.4 | ||
| Cap/Depr | 304.79% | ||
| Cap/Sales | 4.99% | ||
| Interest Coverage | 15.23 | ||
| Cash Conversion | 37.13% | ||
| Profit Quality | 19.39% | ||
| Current Ratio | 7.13 | ||
| Quick Ratio | 3.65 | ||
| Altman-Z | 22.18 |
F-Score7
WACC8.77%
ROIC/WACC2.94
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y19.68%
EPS Next 2Y36.5%
EPS Next 3Y36.8%
EPS Next 5Y33.9%
Revenue 1Y (TTM)27.62%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%12%
Revenue Next Year20.91%
Revenue Next 2Y22.61%
Revenue Next 3Y24.25%
Revenue Next 5Y21.48%
EBIT growth 1Y45.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.58%
EBIT Next 3Y47.86%
EBIT Next 5Y37.89%
FCF growth 1Y272.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y501.56%
OCF growth 3YN/A
OCF growth 5YN/A
ADMA BIOLOGICS INC / ADMA FAQ
What is the fundamental rating for ADMA stock?
ChartMill assigns a fundamental rating of 7 / 10 to ADMA.
Can you provide the valuation status for ADMA BIOLOGICS INC?
ChartMill assigns a valuation rating of 6 / 10 to ADMA BIOLOGICS INC (ADMA). This can be considered as Fairly Valued.
How profitable is ADMA BIOLOGICS INC (ADMA) stock?
ADMA BIOLOGICS INC (ADMA) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ADMA BIOLOGICS INC (ADMA) stock?
The Price/Earnings (PE) ratio for ADMA BIOLOGICS INC (ADMA) is 36.61 and the Price/Book (PB) ratio is 10.91.
Can you provide the financial health for ADMA stock?
The financial health rating of ADMA BIOLOGICS INC (ADMA) is 8 / 10.